Navigation Links
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Date:10/23/2007

drugs to show activity in these tumor types.

While initially effective in treating cancer, many tumors ultimately develop resistance to standard platinum agents. Prior attempts at developing tri-nuclear platinum containing drug candidates proved disappointing when tested in human clinical trials due to extensive protein binding and de-platination in the bloodstream. These novel second-generation bis-platinate compounds utilize butyrate or carboxylate moieties to improve their pharmacokinetic and pharmacodynamic profiles overcoming the limitations of prior multinuclear based compounds. They were developed to be stable in human plasma while circumventing standard palatinate resistance by causing bi-functional long range inter-strand and intra-strand DNA cross links.

About Platinum Anticancer Agents

Platinum agents are the most broadly used cytotoxic drugs used in the war on cancer. They are part of first-line therapeutic regimens for many common cancers including non-small cell lung, ovarian, colorectal, and testicular cancers. Three important monoplatinates are in common use including, carboplatin for lung and ovarian cancers, oxaliplatin for colorectal cancer, and cisplatin for testicular, lung and ovarian cancers. Global sales of platinum based drugs exceeded $1.5 Billion in 2006.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of our bis-platinate drug candidates, CT-47613 and CT-47609, include ri
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014. Applied DNA Sciences, ... provides DNA-based authentication and security solutions and services, has ... Life Sciences, a newly created position, with a starting ... lead APDN’s drive to build its business in pharmaceuticals ... customers, provide guidance to APDN’s R&D efforts, and apply ...
(Date:7/30/2014)... July 30, 2014  Dyadic International, Inc. ("Dyadic") ... patented and proprietary technologies are used to discover, ... for the bioenergy, bio-based chemical, biopharmaceutical and industrial ... "Tom" Dubinski as Vice President and Chief Financial ... financial and information technology operations for Dyadic and ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 NCERC ... Athmanathan will present his findings on corn stover ... conference this week in Washington, D.C. , ... Energy conference is a testament to the success ... Caupert said. “Thanks to the foresight and vision ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
Breaking Biology Technology:Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 2NCERC at SIUE Researcher Takes Stage at Department of Energy Conference 3
... Nektar Therapeutics (Nasdaq: NKTR ) today reported its financial ... Net loss for the quarter ended September 30, 2009 improved to ... loss of $37.0 million or $0.40 per share in the third ... improvements to its operating efficiencies as compared to a year ago. ...
... /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company ... on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today ... Department of Health and Human Services (HHS) to present ... November 5, 2009 at 2:40 pm (EST) at the ...
... Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), announced ... discussing the Company,s 2009 third quarter results on Tuesday, November ... Chairman & Chief Executive Officer, as well as other members ... the Company. A press release reporting the 2009 third quarter ...
Cached Biology Technology:Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10Medicago to present at the U.S. Department of Health and Human Services' Global Health Security Initiative Workshop 2Advanced Life Sciences to Host 2009 Third Quarter Financial Results Conference Call and Webcast 2
(Date:7/30/2014)... studying the potential effects of climate change on ... on the wrong factors, according to a new ... Conservation Society, University of Queensland, and other organizations. ... science is missing the point when it comes ... of climate change scientists focus on the "direct" ...
(Date:7/30/2014)... a joint venture between The University of Texas at ... Science Center at San Antonio, has selected the winners ... Boice from UTSA and Lei Huang from the Health ... "Novel engineered ferritins for tracking and protecting neural stem ... is focused on finding a treatment for stroke through ...
(Date:7/30/2014)... by Clemson University associate professor Andrew S. Mount, performed ... the way for novel anti-fouling paint for ships and ... applications. , The team,s findings, published in ... of barnacles that attaches to a wide variety of ... acts as an underwater heavy-duty adhesive. , "In previous ...
Breaking Biology News(10 mins):Conservation scientists asking wrong questions on climate change impacts on wildlife 2Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... Clemson University assistant professor of engineering and ... National Science Foundation Faculty Early Career Development (CAREER) ... students, decisions to enter engineering fields. Trenor ... theory of social capital to better understand undergraduate ...
... in Spanish . , Increasing calcium intake is ... a study supported in part by the Agricultural Research Service ... to help the body utilize calcium. The study also may ... with this problem. Currently, calcium intake recommendations are not ...
... a bacterium found in about 50% of humans worldwide, can cause ... for F1000 Medicine Reports , Seiji Shiota and Yoshio Yamaoka ... Infection by the H. pylori bacterium can approach ... but many develop problems including stomach ulcers. H. pylori ...
Cached Biology News:Clemson researcher receives grant to study engineering enrollment of women, minorities 2Vitamin D and calcium interplay explored 2Preventing gastric cancer with antibiotics 2